Statement: Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.
Primary_evidence: Adverse Events 1:   Total: 5/26 (19.23%)   Febrile neutropenia 1/26 (3.85%)   Abdominal pain 0/26 (0.00%)   Constipation 0/26 (0.00%)   Nausea 1/26 (3.85%)   Pancreatitis 1/26 (3.85%)   Vomiting 2/26 (7.69%)   Pain 0/26 (0.00%)   Pneumonia 0/26 (0.00%)   Urinary tract infection 1/26 (3.85%)   Lumbar vertebral fracture 1/26 (3.85%)   Ammonia increased 1/26 (3.85%)   Hepatic encephalopathy 1/26 (3.85%) Adverse Events 2:   Total: 4/13 (30.77%)   Febrile neutropenia 1/13 (7.69%)   Abdominal pain 1/13 (7.69%)   Constipation 1/13 (7.69%)   Nausea 0/13 (0.00%)   Pancreatitis 0/13 (0.00%)   Vomiting 0/13 (0.00%)   Pain 1/13 (7.69%)   Pneumonia 1/13 (7.69%)   Urinary tract infection 0/13 (0.00%)   Lumbar vertebral fracture 0/13 (0.00%)   Ammonia increased 0/13 (0.00%)   Hepatic encephalopathy 0/13 (0.00%)